Updates are available Correction dated 2025-03-31
Click to view Correction: https://doi.org/10.1007/s00277-025-06333-x
-
Authors
Costa, Luciano J. https://orcid.org/0000-0001-5362-2469
Gay, Francesca https://orcid.org/0000-0002-8619-412X
Landgren, Ola https://orcid.org/0000-0001-6485-4839
Mateos, María-Victoria https://orcid.org/0000-0003-2390-1218
Moreau, Philippe https://orcid.org/0000-0003-1780-8746
Touzeau, Cyrille https://orcid.org/0000-0003-0275-2575
Ertel, Franziska https://orcid.org/0009-0006-6970-303X
McFadden, Ian https://orcid.org/0009-0004-7488-8804
Najdi, Rani
Weisel, Katja https://orcid.org/0000-0001-9422-6614
-
Funding
Funding for this research was provided by:
Amgen
- License Information
-
More Information
Article History
Received: 24 September 2024
Accepted: 10 December 2024
First Online: 8 January 2025
Change Date: 31 March 2025
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s00277-025-06333-x
Declarations
:
: N/A.
: N/A
: L.J.C. received research funding from Amgen, BMS, Caribou, Genentech, and Janssen; and honoraria from Adaptive Biotechnologies, Amgen, BMS, Janssen, and Pfizer. F.G. reports consulting fees from Amgen, BMS, Oncopeptides, Pfizer, and Roche; honoraria from AbbVie, Amgen, BMS, Janssen, Sanofi, and Takeda; and data safety monitoring or advisory board participation from AbbVie, Amgen, BMS, Janssen, Oncopeptides, Pfizer, Roche, Sanofi, and Takeda. O.L. acknowledges funding from Amgen, Celgene, FDA, Glenmark, IMF, Janssen, Karyopharm Therapeutics, LLS, MMRF, Myeloma Solutions Fund, NCI/NIH, Paula and Rodger Riney Foundation, Perelman Family Foundation, Rising Tide Foundation, Seattle Genetics, Takeda, and Tow Foundation; honoraria for scientific talks/participation in advisory boards for AbbVie, Adaptive, Amgen, Binding Site, BMS, Celgene, GSK, Janssen, Juno, and Pfizer; and serving on Independent Data Monitoring Committees (IDMCs) for international randomized trials by Janssen, Merck, Novartis, and Takeda. M-V.M. reports consulting fees from Amgen, GSK, Janssen, Seagen, and Takeda; honoraria and data safety monitoring or advisory board participation from AbbVie, Amgen, Celgene, GSK, Janssen, Oncopeptides, Pfizer, Regeneron, Roche, Sanofi, and Takeda. P.M. reports advisory board participation and honoraria from AbbVie, Amgen, BMS, Celgene, Janssen, Pfizer, Sanofi, and Takeda. C.T. received honoraria from and served in a consulting or advisory role for AbbVie, Amgen, Celgene, Janssen, and Takeda; and had travel, accommodations or other expenses paid or reimbursed by AbbVie, Amgen, Janssen, and Takeda. F.E., I.M., and R.N. are employees of Amgen. K.W. has served in a consulting or advisory role for Adaptive Biotechnologies, Amgen, BMS, Celgene, GSK, Janssen-Cilag, Karyopharm Therapeutics, Oncopeptides, Roche, Sanofi, and Takeda; received travel, accommodations, and/or expenses from Amgen, BMS, Celgene, GSK, Janssen-Cilag, and Takeda; honoraria from AbbVie, Adaptive Biotechnologies, Amgen, BMS, Celgene, GSK, Janssen-Cilag, Karyopharm Therapeutics, Novartis, Oncopeptides, Pfizer, Roche/Genentech, Sanofi, and Takeda; and research funding from Amgen, BMS, Celgene, GSK, Janssen-Cilag, and Sanofi.
